Cargando…

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm with a prevalence of 4 to 6 per 100,000 people in the USA. Treatment recommendations are risk-adapted. This study was conducted to evaluate how physicians risk-stratify patients at the time of MF diagnosis, the accuracy of the risk stratifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verstovsek, Srdan, Yu, Jingbo, Kish, Jonathan K., Paranagama, Dilan, Kaufman, Jill, Myerscough, Callan, Grunwald, Michael R., Colucci, Philomena, Mesa, Ruben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536164/ https://www.ncbi.nlm.nih.gov/pubmed/32382773 http://dx.doi.org/10.1007/s00277-020-04055-w

Ejemplares similares

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States
por: Grunwald, Michael R., et al.
Publicado: (2018)

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
por: Mesa, Ruben, et al.
Publicado: (2018)

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study
por: Zwicker, Jeffrey I., et al.
Publicado: (2021)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2019)

Defining disease modification in myelofibrosis in the era of targeted therapy
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2020)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
por: Mughal, Tariq I, et al.
Publicado: (2014)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
por: Yu, Jingbo, et al.
Publicado: (2018)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
por: Verstovsek, Srdan, et al.
Publicado: (2013)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
por: Veletic, Ivo, et al.
Publicado: (2020)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
por: Manshouri, Taghi, et al.
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
por: Verstovsek, Srdan, et al.
Publicado: (2017)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey
por: Yu, Jingbo, et al.
Publicado: (2020)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
por: Harrison, Claire N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_66m6kfv3m66076kr2fd1ua8eqd